Valore20202021202220232024TTMFlussi di cassa derivanti dalle attività di investimento-42.88 M-524.41 M-26.95 M-116.78 M350.44 M249.61 MLiquidità derivante dalle attività di finanziamento-14.8 M586 K-546.05 M-628.81 M-969.59 M-1.13 BLiquidità libera400.8 M362.61 M333.32 M699.97 M875.84 M917.69 M
Exelixis, Inc. - Common Stock
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.